tetano
Editor, Senior Moderator
J Korean Med Sci
. 2024 Apr 22;39(15):e146.
doi: 10.3346/jkms.2024.39.e146. Interim Estimates of 2023-2024 Seasonal Influenza Vaccine Effectiveness Among Adults in Korea
Yu Jung Choi[SUP] 1 2 [/SUP], Jang Wook Sohn[SUP] 1 2 [/SUP], Won Suk Choi[SUP] 1 2 [/SUP], Seong-Heon Wie[SUP] 3 [/SUP], Jacob Lee[SUP] 4 [/SUP], Jin-Soo Lee[SUP] 5 [/SUP], Hye Won Jeong[SUP] 6 [/SUP], Joong Sik Eom[SUP] 7 [/SUP], Eliel Nham[SUP] 1 2 [/SUP], Hye Seong[SUP] 1 2 [/SUP], Jin Gu Yoon[SUP] 1 2 [/SUP], Ji Yun Noh[SUP] 1 2 [/SUP], Joon Young Song[SUP] 1 2 [/SUP], Hee Jin Cheong[SUP] 1 2 [/SUP], Woo Joo Kim[SUP] 1 8 [/SUP]
Affiliations
In the 2023-2024 season, the influenza epidemic in South Korea peaked earlier than in recent years. In this study, we aimed to estimate the interim vaccine effectiveness (VE) of the influenza vaccination to prevent influenza during the early season. From November 1, 2023, to December 31, 2023, we enrolled 2,632 subjects with influenza-like illness from eight hospitals participating in hospital-based influenza morbidity and mortality surveillance. A retrospective test-negative case-control study was conducted to estimate the VE. The results showed an adjusted VE of 22.5% (95% confidence interval [CI], 6.6 to 35.8) for the total population. The adjusted VE was 22.3% (95% CI, 6.1 to 35.7) for influenza A and 9.4% (95% CI, -51.3 to 45.7) for influenza A/H1N1. Full results of the analysis will be reported.
Keywords: Influenza; Influenza Vaccine; Vaccination; Vaccine Effectiveness.
. 2024 Apr 22;39(15):e146.
doi: 10.3346/jkms.2024.39.e146. Interim Estimates of 2023-2024 Seasonal Influenza Vaccine Effectiveness Among Adults in Korea
Yu Jung Choi[SUP] 1 2 [/SUP], Jang Wook Sohn[SUP] 1 2 [/SUP], Won Suk Choi[SUP] 1 2 [/SUP], Seong-Heon Wie[SUP] 3 [/SUP], Jacob Lee[SUP] 4 [/SUP], Jin-Soo Lee[SUP] 5 [/SUP], Hye Won Jeong[SUP] 6 [/SUP], Joong Sik Eom[SUP] 7 [/SUP], Eliel Nham[SUP] 1 2 [/SUP], Hye Seong[SUP] 1 2 [/SUP], Jin Gu Yoon[SUP] 1 2 [/SUP], Ji Yun Noh[SUP] 1 2 [/SUP], Joon Young Song[SUP] 1 2 [/SUP], Hee Jin Cheong[SUP] 1 2 [/SUP], Woo Joo Kim[SUP] 1 8 [/SUP]
Affiliations
- PMID: 38651226
- PMCID: PMC11035711
- DOI: 10.3346/jkms.2024.39.e146
In the 2023-2024 season, the influenza epidemic in South Korea peaked earlier than in recent years. In this study, we aimed to estimate the interim vaccine effectiveness (VE) of the influenza vaccination to prevent influenza during the early season. From November 1, 2023, to December 31, 2023, we enrolled 2,632 subjects with influenza-like illness from eight hospitals participating in hospital-based influenza morbidity and mortality surveillance. A retrospective test-negative case-control study was conducted to estimate the VE. The results showed an adjusted VE of 22.5% (95% confidence interval [CI], 6.6 to 35.8) for the total population. The adjusted VE was 22.3% (95% CI, 6.1 to 35.7) for influenza A and 9.4% (95% CI, -51.3 to 45.7) for influenza A/H1N1. Full results of the analysis will be reported.
Keywords: Influenza; Influenza Vaccine; Vaccination; Vaccine Effectiveness.